公开(公告)号：US20230173003A1

公开(公告)日：2023-06-08

申请号：US17941310

申请日：2022-09-09

Applicant: MAGI EUREGIO SCS

Inventor： Matteo Bertelli ,  Elena Manara ,  Paolo Enrico Maltese ,  Stefano Cecchin ,  Giuseppe Marceddu ,  Kyrylo Anpilogov ,  Stefano Paolacci ,  Daniele Malacarne ,  Teresa Zelante ,  Stefano Giovagnoli ,  Debora Caricato ,  Leonardo Brizzi

IPC: A61K35/747 ,  A61K9/00 ,  A61K47/10 ,  A61K47/38 ,  A61P1/02

CPC classification number: A61K35/747 ,  A61K9/006 ,  A61K47/10 ,  A61K47/38 ,  A61P1/02

Abstract: A composition, in particular in gel form, includes Lactobacillaceae reuteri to be used in the prevention and/or treatment of oral mucositis, particularly radio-induced oral mucositis. In its gel form, the composition also includes: a polyoxy-alkylene copolymer, in particular a polyoxy-ethylene-propylene copolymer, preferably with the general formula HO[CH2CH2O]x[CH2CH(CH3)O]y[CH2CH2O]zH, where preferably x=99, y=67, and z=99; a mucoadhesive polymer, preferably cellulosic in nature, in particular carboxymethyl cellulose; and one or more stabilizers, preferably chosen from sugars such as sucrose, trehalose, mannitol, sorbitol and glucose, sodium ascorbate, very preferably the sugar is sucrose. Treatments of other mucositis with the composition, such as intestinal leakage, are conceivable. A procedure to produce the composition in gel and lyophilized form is described.

公开(公告)号：US20220362260A1

公开(公告)日：2022-11-17

申请号：US17734708

申请日：2022-05-02

Applicant: MAGI EUREGIO SCS

Inventor： Matteo Bertelli ,  Elena Manara ,  Paolo Enrico Maltese ,  Sandro Michelini ,  Serena Michelini ,  Maria Rachele Ceccarini ,  Pietro Chiurazzi ,  Karen Louise Herbst

IPC: A61K31/551 ,  A61K31/4035 ,  A61K31/196 ,  A61K31/353 ,  A61K31/7048 ,  A61K31/566 ,  A61K31/57 ,  A61K31/7034 ,  A61K36/05 ,  A61K36/82 ,  A61K31/201 ,  A61K31/704 ,  A61K31/231 ,  A61K31/16 ,  A61K31/122 ,  A61K31/60 ,  A61K31/603 ,  A61K31/19 ,  A61K31/05 ,  A61K31/37 ,  A61K31/366 ,  A61K31/121 ,  A61K31/192 ,  A61K33/40 ,  A61K36/38 ,  A61K31/567 ,  A61K31/22 ,  A61K31/405 ,  A61K31/415 ,  A61K31/167 ,  A61K31/616 ,  A61K31/407 ,  A61K31/40 ,  A61K31/585 ,  A61K31/575 ,  A61K31/138 ,  A61K31/365 ,  A61K31/352 ,  A61K31/5517 ,  C12Q1/6883 ,  C12Q1/32 ,  G01N33/68

Abstract: The present invention identifies AKR1C1 as the first lipedema-associated gene. The invention provides methods for diagnosing or assessing an individual's susceptibility to lipedema by the analysis of the AKR1C1 gene or the expression levels of its product and related metabolites. Also provided are therapeutic methods for treating a patient or methods for prophylactically treating an individual susceptible to lipedema.